Document is current
Any future updates will be listed below
-
Authors
Roudko, Vladimir
Del Valle, Diane Marie https://orcid.org/0000-0001-6983-5362
Radkevich, Emir
Kelly, Geoffrey
Hui, Xie
Patel, Manishkumar
Gonzalez-Kozlova, Edgar
Tuballes, Kevin
Streicher, Howard
Atale, Swati
Wang, Lisa
CzinCzin, Benito
Kim-Schulze, Seunghee
Wistuba, Ignacio I
Haymaker, Cara L https://orcid.org/0000-0002-1317-9287
Al-Atrash, Gheath
Manyam, Ganiraju
Zhang, Jianjun https://orcid.org/0000-0001-7872-3477
Thompson, Ryan
Suarez-Farinas, Mayte
Lheureux, Stephanie
Gnjatic, Sacha
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03367741 at ClinicalTrials.govnct03367741 at ClinicalTrials.govDocuments that mention this clinical trial
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer
https://doi.org/10.1136/jitc-2021-004233
Molecular typing guiding treatment and prognosis of endometrial cancer
https://doi.org/10.1016/j.gocm.2023.01.011
Immunological biomarkers of response and resistance to treatment with cabozantinib and nivolumab in recurrent endometrial cancer
https://doi.org/10.1136/jitc-2024-010541
nct03367741 at ClinicalTrials.govDocuments that mention this clinical trial
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer
https://doi.org/10.1136/jitc-2021-004233
Molecular typing guiding treatment and prognosis of endometrial cancer
https://doi.org/10.1016/j.gocm.2023.01.011
Immunological biomarkers of response and resistance to treatment with cabozantinib and nivolumab in recurrent endometrial cancer
https://doi.org/10.1136/jitc-2024-010541
nct03367741 at ClinicalTrials.govDocuments that mention this clinical trial
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer
https://doi.org/10.1136/jitc-2021-004233
Molecular typing guiding treatment and prognosis of endometrial cancer
https://doi.org/10.1016/j.gocm.2023.01.011
Immunological biomarkers of response and resistance to treatment with cabozantinib and nivolumab in recurrent endometrial cancer
https://doi.org/10.1136/jitc-2024-010541
nct03367741 at ClinicalTrials.govDocuments that mention this clinical trial
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer
https://doi.org/10.1136/jitc-2021-004233
Molecular typing guiding treatment and prognosis of endometrial cancer
https://doi.org/10.1016/j.gocm.2023.01.011
Immunological biomarkers of response and resistance to treatment with cabozantinib and nivolumab in recurrent endometrial cancer
https://doi.org/10.1136/jitc-2024-010541
nct03367741 at ClinicalTrials.govDocuments that mention this clinical trial
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer
https://doi.org/10.1136/jitc-2021-004233
Molecular typing guiding treatment and prognosis of endometrial cancer
https://doi.org/10.1016/j.gocm.2023.01.011
Immunological biomarkers of response and resistance to treatment with cabozantinib and nivolumab in recurrent endometrial cancer
https://doi.org/10.1136/jitc-2024-010541
Documents that mention this clinical trial
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer
https://doi.org/10.1136/jitc-2021-004233
Molecular typing guiding treatment and prognosis of endometrial cancer
https://doi.org/10.1016/j.gocm.2023.01.011
Immunological biomarkers of response and resistance to treatment with cabozantinib and nivolumab in recurrent endometrial cancer
https://doi.org/10.1136/jitc-2024-010541
-
Funding
Funding for this research was provided by:
National Cancer Institute (140D0421D0007)
National Cancer Institute (P30CA196521)
National Cancer Institute (R33CA263705)
National Cancer Institute (U01DK124165)
National Cancer Institute (U24CA224285)
National Cancer Institute (U24CA224316)
National Cancer Institute (U24CA224319)
National Cancer Institute (U24CA224331)
National Center for Advancing Translational Sciences (UL1TR004419)
Conquer Cancer Foundation (2019 Career Development Award)
- License Information
